Maria Luisa Pineda
About Maria Luisa Pineda
Maria Luisa Pineda is the co-founder and CEO of Envisagenics, known for her extensive background in science and investment in technology and life-sciences startups.
Maria Luisa Pineda - Co-founder & CEO
Maria Luisa Pineda is the Co-founder and CEO of Envisagenics. Under her leadership, Envisagenics has successfully secured non-dilutive SBIR grants from the National Institutes of Health and raised capital from investors. The company has also been recognized by winning several prestigious artificial intelligence competitions and has formed multiple research collaboration partnerships with leading Biopharma companies.
Maria Luisa Pineda's Education and Expertise
Maria Luisa Pineda's academic journey began as a high school Intel International Science Fair winner. She pursued her undergraduate studies with the support of a $2 million endowment from the Goizueta Foundation. Further advancing her expertise, she received an NIH fellowship through the Minority Access to Research Careers (MARC U*STAR) program. Maria obtained her Doctorate from Cold Spring Harbor Laboratory School of Biological Sciences, where she was an Arnold and Mabel Beckman graduate student and a William Randolph Hearst Foundation scholar.
Maria Luisa Pineda's Background in Science and Investment
In addition to her academic achievements, Maria Luisa Pineda has acquired investment experience in both technology and life-sciences startup companies. She has held roles at Canrock Ventures and Golden Seeds, LLC, where she honed her skills in evaluating and supporting early-stage companies in these sectors. Her background seamlessly integrates scientific research with strategic investment, contributing to her leadership role at Envisagenics.
Achievements of Maria Luisa Pineda
Maria Luisa Pineda has a notable track record of accomplishments. She started her career as a high school Intel International Science Fair winner and later received a significant endowment for her undergraduate studies. In her professional career, she has led Envisagenics to success through securing NIH SBIR grants, raising substantial investment capital, and winning artificial intelligence competitions. Under her guidance, Envisagenics has also established fruitful research collaborations with Biopharma companies.